Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Canada.
Department of Obstetrics and Gynecology, University of Calgary Cumming School of Medicine, Calgary, Canada.
Thyroid. 2021 May;31(5):841-849. doi: 10.1089/thy.2020.0609. Epub 2020 Nov 26.
Women with hypothyroidism before pregnancy often require an increase in their levothyroxine dosage to maintain a euthyroid state during pregnancy. The objectives of this study were to investigate: (i) the frequency and distribution of thyrotropin (TSH) testing and levothyroxine dosage adjustment by gestational age, (ii) the magnitude of levothyroxine increase by the underlying etiology of hypothyroidism, and (iii) the relationship of overtreatment or undertreatment during pregnancy with adverse pregnancy outcomes among women using thyroid replacement before pregnancy. A retrospective cohort study of pregnancies in women on thyroid replacement before pregnancy in Alberta, Canada, was performed. Women using thyroid replacement anytime during the two years before pregnancy who delivered between October 2014 and September 2017 were included. Delivery records, physician billing, and laboratory and pharmacy administrative data were linked. Outcomes included characteristics of TSH testing, levothyroxine dosing, and pregnancy outcomes. The frequency and gestational timing of TSH testing and levothyroxine adjustments were calculated. Multiple logistic regression was used to test whether pregnancies with TSH <0.10 mIU/L (overtreatment) or TSH ≥10.00 mIU/L (undertreatment) compared with control pregnancies (TSH 0.10-4.00 mIU/L) were associated with adverse pregnancy and neonatal outcomes. Of the 10,680 deliveries, 8774 (82.2%) underwent TSH testing at least once during pregnancy, at a median gestational age of six weeks. An adjustment of levothyroxine dosage was made for 4321 (43.7%) during pregnancy. TSH in pregnancy below 0.10 mIU/L increased the odds of preterm delivery when compared with control pregnancies (adjusted odds ratio, 2.14 [95% confidence interval 1.51-2.78]). TSH ≥10.00 mIU/L during pregnancy was not associated with any adverse pregnancy or neonatal outcomes in the multivariable analysis. Although most women on thyroid replacement before conception had TSH measured at some point during pregnancy, it is concerning that 17.8% did not. Levothyroxine overtreatment in pregnancy was associated with preterm delivery. These findings suggest that clinicians should be careful to avoid overtreatment with levothyroxine in pregnancy.
患有甲状腺功能减退症的女性在怀孕前通常需要增加左甲状腺素的剂量,以在怀孕期间维持甲状腺功能正常。本研究的目的是:(i)按妊娠周龄检测促甲状腺激素(TSH)和调整左甲状腺素剂量的频率和分布;(ii)根据甲状腺功能减退症的潜在病因,确定左甲状腺素增加的幅度;(iii)研究在怀孕前使用甲状腺替代治疗的女性中,怀孕期间的过度治疗或治疗不足与不良妊娠结局之间的关系。在加拿大阿尔伯塔省进行了一项回顾性队列研究,纳入了在怀孕前两年内任何时间使用甲状腺替代治疗的孕妇,这些孕妇在 2014 年 10 月至 2017 年 9 月间分娩。将分娩记录、医生计费以及实验室和药房行政数据进行了关联。结果包括 TSH 检测、左甲状腺素剂量和妊娠结局的特征。计算了 TSH 检测和左甲状腺素调整的频率和妊娠周龄。采用多因素逻辑回归检验 TSH<0.10 mIU/L(过度治疗)或 TSH≥10.00 mIU/L(治疗不足)的妊娠与 TSH 0.10-4.00 mIU/L 的对照妊娠相比,是否与不良妊娠和新生儿结局相关。在 10680 例分娩中,8774 例(82.2%)在妊娠期间至少进行过一次 TSH 检测,中位数为妊娠 6 周。4321 例(43.7%)在妊娠期间调整了左甲状腺素剂量。与对照妊娠相比,妊娠期间 TSH 低于 0.10 mIU/L 增加了早产的风险(调整后的比值比,2.14 [95%置信区间 1.51-2.78])。多变量分析显示,妊娠期间 TSH≥10.00 mIU/L 与任何不良妊娠或新生儿结局无关。尽管大多数在妊娠前服用甲状腺替代药物的女性在妊娠期间的某个时间点进行了 TSH 检测,但令人担忧的是,仍有 17.8%的女性未进行检测。妊娠期间左甲状腺素过度治疗与早产有关。这些发现表明,临床医生在怀孕期间应注意避免过度使用左甲状腺素治疗。